BioLife Solutions (BLFS) Expected to Release Earnings on Thursday

BioLife Solutions (NASDAQ:BLFS) is expected to be announcing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect BioLife Solutions to post earnings of ($0.01) per share and revenue of $27.7960 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. BioLife Solutions had a positive return on equity of 1.81% and a negative net margin of 2.80%.The company had revenue of $27.50 million during the quarter, compared to analysts’ expectations of $25.66 million. On average, analysts expect BioLife Solutions to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioLife Solutions Stock Performance

Shares of BLFS stock opened at $31.50 on Thursday. BioLife Solutions has a fifty-two week low of $17.86 and a fifty-two week high of $33.14. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of -393.70 and a beta of 1.94. The stock’s 50-day simple moving average is $27.42 and its 200-day simple moving average is $23.65.

Insiders Place Their Bets

In other BioLife Solutions news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of BioLife Solutions stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $23.70, for a total transaction of $15,405,000.00. Following the completion of the transaction, the insider owned 4,757,165 shares in the company, valued at approximately $112,744,810.50. This trade represents a 12.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 1,200,000 shares of company stock worth $28,125,000. 2.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On BioLife Solutions

Several hedge funds have recently bought and sold shares of the stock. Comerica Bank increased its holdings in shares of BioLife Solutions by 27.0% during the 3rd quarter. Comerica Bank now owns 18,792 shares of the medical equipment provider’s stock valued at $479,000 after purchasing an additional 3,991 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in BioLife Solutions by 2.7% during the second quarter. The Manufacturers Life Insurance Company now owns 20,764 shares of the medical equipment provider’s stock worth $447,000 after buying an additional 555 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in BioLife Solutions by 59.5% during the second quarter. BNP Paribas Financial Markets now owns 18,755 shares of the medical equipment provider’s stock worth $404,000 after buying an additional 6,997 shares in the last quarter. Two Sigma Investments LP acquired a new stake in BioLife Solutions during the third quarter valued at $403,000. Finally, PharVision Advisers LLC acquired a new stake in BioLife Solutions during the third quarter valued at $316,000. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Maxim Group downgraded shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. Wall Street Zen lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating in a report on Saturday, July 25th. Jefferies Financial Group lowered BioLife Solutions from a “buy” rating to a “hold” rating and raised their target price for the stock from $30.00 to $31.00 in a research note on Thursday, July 23rd. TD Cowen downgraded BioLife Solutions from a “buy” rating to a “hold” rating and dropped their price target for the company from $33.00 to $31.00 in a research note on Wednesday, July 22nd. Finally, William Blair set a $31.00 price objective on BioLife Solutions in a research note on Thursday, July 23rd. One research analyst has rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $31.38.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.